11/14/2024
Marking Matters - CBP Ruling on Origin Marking for Repackaged Pharmaceutical Medications Sold at Retail
In HQ Ruling H283420 (June 14, 2024), CBP issued an internal advice decision in response to an inquiry from an individual retail purchaser about the country of origin marking requirements for imported prescription medication repackaged by CVS Health.
CBP determined that the retail customer is the ultimate purchaser, as they receive the product in its imported form without substantial transformation. Therefore, the country of origin must be marked on the container that the customer receives at the point of sale.
The ruling concerns Omeprazole, manufactured in India, imported by Sandoz, and originally labeled with its country of origin. CVS repackaged the medication into unmarked containers before selling it to retail customers, raising the question of who qualifies as the "ultimate purchaser"—CVS or the retail customer—under U.S. marking regulations.
CBP clarified that although prescription drugs are exempt from individual marking as J-List articles, the outermost retail container must still display the country of origin. Under the regulations, Sandoz must provide certification to CBP and notice to CVS to ensure the repackaged product is marked in compliance with these requirements.
This decision underscores the obligation for pharmacies repackaging imported medication to clearly display the country of origin on retail containers.